Daily Stock Analysis, ALNY, Alnylam Pharmaceuticals Inc, priceseries

Alnylam Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
90.57
Close
92.05
High
92.39
Low
90.27
Previous Close
90.46
Daily Price Gain
1.59
YTD High
96.08
YTD High Date
Apr 1, 2019
YTD Low
65.81
YTD Low Date
May 20, 2019
YTD Price Change
19.29
YTD Gain
26.51%
52 Week High
96.08
52 Week High Date
Apr 1, 2019
52 Week Low
60.27
52 Week Low Date
Dec 24, 2018
52 Week Price Change
18.89
52 Week Gain
25.82%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 24. 2017
46.62
Mar 13. 2017
50.52
11 Trading Days
8.37%
Link
LONG
May 12. 2017
56.77
May 26. 2017
67.35
10 Trading Days
18.64%
Link
LONG
Jun 1. 2017
69.70
Jun 27. 2017
80.59
18 Trading Days
15.62%
Link
LONG
Mar 7. 2018
123.99
Mar 23. 2018
139.26
12 Trading Days
12.31%
Link
LONG
Nov 23. 2018
73.34
Dec 4. 2018
78.61
7 Trading Days
7.19%
Link
LONG
Dec 28. 2018
70.40
Jan 15. 2019
79.96
11 Trading Days
13.58%
Link
LONG
Oct 11. 2019
78.97
Oct 30. 2019
87.28
13 Trading Days
10.52%
Link
Company Information
Stock Symbol
ALNY
Exchange
NasdaqGS
Company URL
http://www.alnylam.com
Company Phone
(617) 551-8200
CEO
John M. Maraganore
Headquarters
Massachusetts
Business Address
300 THIRD STREET, CAMBRIDGE, MA 02142
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001178670
About

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Description

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. Its pipeline of investigational RNAi therapeutics is focused on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of transthyretin-mediated amyloidosis (ATTR); Fitusiran, an investigational RNAi therapeutic that is in Phase I/II clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran (ALN-PCSsc), which is in Phase II clinical trial for hypercholesterolemia. Its early stage clinical programs include Givosiran that is in Phase I trial to treat acute hepatic porphyrias; ALN-CC5 for the treatment of complement-mediated diseases; ALN-GO1 to treat primary hyperoxaluria 1; ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR for the treatment of various forms of ATTR amyloidosis; and ALN-HBV for the treatment of Hepatitis B virus. The company has strategic alliances and collaboration agreements primarily with Sanofi Genzyme; The Medicines Company; Monsanto Company; Takeda Pharmaceutical Company Limited; Ionis Pharmaceuticals, Inc.; The University of British Columbia; and Acuitas Therapeutics Inc.; and Arbutus Biopharma Corporation. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.